BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BioCentury | Sep 24, 2012
Tools & Techniques

Hypothesis free

A new deal between GNS Healthcare Inc. and Covance Inc. to develop predictive clinical trial models for diabetes is one example of how big data tools are being applied to drug development. Last week, GNS...
BioCentury | Aug 20, 2012
Company News

GNS Healthcare, CHDI Foundation Inc. deal

Data analytics company GNS Healthcare partnered with the not-for-profit foundation to create a computer model of Huntington's disease (HD). GNS is providing its Reverse Engineering and Forward Simulation (REFS) modeling technology, while CHDI is providing...
BioCentury | Aug 15, 2012
Company News

GNS, CHDI to model Huntington's

Data analytics company GNS Healthcare Inc. (Cambridge, Mass.) partnered with the not-for-profit CHDI Foundation Inc. to create a computer model of Huntington's disease. GNS is providing its Reverse Engineering and Forward Simulation (REFS) modeling technology,...
BioCentury | Jun 16, 2011
Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
BioCentury | Mar 14, 2011
Company News

Bavarian Nordic, BGI, Shenzhen, Genomic Expression Inc., Statens Serum Institut, University of Copenhagen cancer news

...partnered with researchers from the university, institute, BGI's Beijing Genomics Institute Europe A/S subsidiary and Genomic Expression...
...Further terms were not disclosed. Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark BGI, Shenzhen , China Genomic Expression Inc....
BioCentury | Jan 17, 2011
Company News

Affymetrix, Thermo Fisher sales and marketing update

Fisher Scientific Inc., part of Thermo Fisher, will distribute the GeneAtlas personal microarray system for whole-genome expression in the U.S. and Canada. Last year, Affymetrix launched the system for use in low- to medium-throughput service...
BioCentury | Jun 14, 2010
Company News

NuView, Thomas Jefferson University deal

NuView received an exclusive license to the university's molecular imaging compound to identify genomic expressions linked to prostate cancer. The gene guided radioactive probe targets elevated levels of the vasoactive intestinal peptide receptor 1 (VPAC1)...
BioCentury | Mar 22, 2010
Product Development

Spies plot revolution

The I-SPY 2 trial, launched last week, is intended to both speed development of compounds for locally advanced breast cancer and to serve as a model for integrating biomarkers, adaptive trial designs, and bioinformatics to...
BioCentury | Mar 22, 2010
Clinical News

AMG 386: Trial started

Agendia B.V. , Amsterdam, the Netherlands Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: AMG 386 ; conatumumab (AMG 655); figitumumab (CP-751,871, CP-751871); neratinib ( HKI-272...
Items per page:
1 - 10 of 41
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BioCentury | Sep 24, 2012
Tools & Techniques

Hypothesis free

A new deal between GNS Healthcare Inc. and Covance Inc. to develop predictive clinical trial models for diabetes is one example of how big data tools are being applied to drug development. Last week, GNS...
BioCentury | Aug 20, 2012
Company News

GNS Healthcare, CHDI Foundation Inc. deal

Data analytics company GNS Healthcare partnered with the not-for-profit foundation to create a computer model of Huntington's disease (HD). GNS is providing its Reverse Engineering and Forward Simulation (REFS) modeling technology, while CHDI is providing...
BioCentury | Aug 15, 2012
Company News

GNS, CHDI to model Huntington's

Data analytics company GNS Healthcare Inc. (Cambridge, Mass.) partnered with the not-for-profit CHDI Foundation Inc. to create a computer model of Huntington's disease. GNS is providing its Reverse Engineering and Forward Simulation (REFS) modeling technology,...
BioCentury | Jun 16, 2011
Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
BioCentury | Mar 14, 2011
Company News

Bavarian Nordic, BGI, Shenzhen, Genomic Expression Inc., Statens Serum Institut, University of Copenhagen cancer news

...partnered with researchers from the university, institute, BGI's Beijing Genomics Institute Europe A/S subsidiary and Genomic Expression...
...Further terms were not disclosed. Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark BGI, Shenzhen , China Genomic Expression Inc....
BioCentury | Jan 17, 2011
Company News

Affymetrix, Thermo Fisher sales and marketing update

Fisher Scientific Inc., part of Thermo Fisher, will distribute the GeneAtlas personal microarray system for whole-genome expression in the U.S. and Canada. Last year, Affymetrix launched the system for use in low- to medium-throughput service...
BioCentury | Jun 14, 2010
Company News

NuView, Thomas Jefferson University deal

NuView received an exclusive license to the university's molecular imaging compound to identify genomic expressions linked to prostate cancer. The gene guided radioactive probe targets elevated levels of the vasoactive intestinal peptide receptor 1 (VPAC1)...
BioCentury | Mar 22, 2010
Product Development

Spies plot revolution

The I-SPY 2 trial, launched last week, is intended to both speed development of compounds for locally advanced breast cancer and to serve as a model for integrating biomarkers, adaptive trial designs, and bioinformatics to...
BioCentury | Mar 22, 2010
Clinical News

AMG 386: Trial started

Agendia B.V. , Amsterdam, the Netherlands Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: AMG 386 ; conatumumab (AMG 655); figitumumab (CP-751,871, CP-751871); neratinib ( HKI-272...
Items per page:
1 - 10 of 41